faculty

Publications

Home / Publications / An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy

An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy

Groups and Associations Michelle L Schoettler 1, Eleni Gavriilaki 2, Enric Carreras 3, Cho Bo-Kyoung 4, Christopher E Dandoy 5, Vincent T Ho 6, Sonata Jodele 5, Ivan Moiseev 7, Isabella Sánchez-Ortega 8, Alok Srivastava 9, Yoshiko Atsuta 10, Paul A Carpenter 11, John Koreth 6, Nicolaus Kröger 12, Per Ljungman 13, Kristen Page 14, Uday Popat 15, Bronwen E Shaw 16, Ana Maria Sureda 17, Robert Soiffer 6, Sumithira Vasu 18
Transplant Cell Ther 2023

Background: Transplant associated thrombotic microangiopathy (TA-TMA) confers significant morbidity and mortality in hematopoietic cell transplant recipients. The safety and efficacy of multiple TA-TMA directed therapeutic agents are being tested in ongoing clinical trials. In the absence of approved drugs, several treatments are used off-label. Response definitions to TA-TMA directed therapy from retrospective studies and ongoing interventional clinical trials vary widely, limiting cross study comparisons. An expert panel from multiple international blood and marrow transplant societies (ASTCT, CIBMTR, EBMT, APBMT) who initially convened to harmonize diagnostic and risk stratification criteria for TA-TMA extended its mandate to review response criteria.